CL2012001103A1 - Método para reducir el nivel del polipéptido tau desacetilado en una célula, que comprende poner en contacto la célula con un agente que incrementa la actividad de un polipéptido que desacetila tau y/o un agente que disminuye la actividad de un polipéptido que acetila tau; y usos terapéuticos para tratar una tauopatía. - Google Patents

Método para reducir el nivel del polipéptido tau desacetilado en una célula, que comprende poner en contacto la célula con un agente que incrementa la actividad de un polipéptido que desacetila tau y/o un agente que disminuye la actividad de un polipéptido que acetila tau; y usos terapéuticos para tratar una tauopatía.

Info

Publication number
CL2012001103A1
CL2012001103A1 CL2012001103A CL2012001103A CL2012001103A1 CL 2012001103 A1 CL2012001103 A1 CL 2012001103A1 CL 2012001103 A CL2012001103 A CL 2012001103A CL 2012001103 A CL2012001103 A CL 2012001103A CL 2012001103 A1 CL2012001103 A1 CL 2012001103A1
Authority
CL
Chile
Prior art keywords
polypeptide
tau
activity
cell
agent
Prior art date
Application number
CL2012001103A
Other languages
English (en)
Inventor
Li Gan
Original Assignee
The J David Gladstone Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43970226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001103(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The J David Gladstone Inst filed Critical The J David Gladstone Inst
Publication of CL2012001103A1 publication Critical patent/CL2012001103A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G01N33/555—Red blood cell
    • G01N33/556—Fixed or stabilised red blood cell

Abstract

Método para reducir el nivel del polipéptido tau desacetilado en una célula, que comprende poner en contacto la célula con un agente que incrementa la actividad de un polipéptido que desacetila tau y/o un agente que disminuye la actividad de un polipéptido que acetila tau; y usos terapéuticos para tratar una tauopatía.
CL2012001103A 2009-11-06 2012-04-27 Método para reducir el nivel del polipéptido tau desacetilado en una célula, que comprende poner en contacto la célula con un agente que incrementa la actividad de un polipéptido que desacetila tau y/o un agente que disminuye la actividad de un polipéptido que acetila tau; y usos terapéuticos para tratar una tauopatía. CL2012001103A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25882209P 2009-11-06 2009-11-06

Publications (1)

Publication Number Publication Date
CL2012001103A1 true CL2012001103A1 (es) 2012-11-05

Family

ID=43970226

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001103A CL2012001103A1 (es) 2009-11-06 2012-04-27 Método para reducir el nivel del polipéptido tau desacetilado en una célula, que comprende poner en contacto la célula con un agente que incrementa la actividad de un polipéptido que desacetila tau y/o un agente que disminuye la actividad de un polipéptido que acetila tau; y usos terapéuticos para tratar una tauopatía.

Country Status (15)

Country Link
US (2) US9040521B2 (es)
EP (1) EP2496594B1 (es)
JP (1) JP5851409B2 (es)
KR (1) KR20120101053A (es)
CN (1) CN102791725A (es)
AU (1) AU2010315780A1 (es)
BR (1) BR112012010587A2 (es)
CA (2) CA2990678C (es)
CL (1) CL2012001103A1 (es)
DK (1) DK2496594T3 (es)
EA (1) EA201290194A1 (es)
IL (1) IL219445A0 (es)
MX (1) MX2012005300A (es)
WO (1) WO2011056300A1 (es)
ZA (1) ZA201202923B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102791725A (zh) * 2009-11-06 2012-11-21 J.大卫格莱斯顿学会 调节tau水平的方法和组合物
ES2656442T3 (es) * 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
US9567395B2 (en) 2012-08-16 2017-02-14 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
WO2015061856A1 (en) * 2013-10-30 2015-05-07 University Of Western Australia Neuroprotective peptides
CN111569063A (zh) * 2013-11-27 2020-08-25 伊皮埃里安股份有限公司 治疗tau病变的方法
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR20230097209A (ko) 2014-03-12 2023-06-30 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
WO2016115520A1 (en) * 2015-01-16 2016-07-21 The J. David Gladstone Institutes Methods for treating tauopathy
WO2017011748A1 (en) * 2015-07-15 2017-01-19 Northwestern University Ipsc-ec performance enhancement via sirt1 overexpression
WO2018106889A1 (en) * 2016-12-09 2018-06-14 Cogwellin L.L.C. Diagnosis of alzheimer's disease
KR102032314B1 (ko) * 2016-12-21 2019-10-16 주식회사 아델 변이된 타우 단백질 단편 및 이의 용도
JP7278960B2 (ja) * 2017-03-28 2023-05-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新規タウ種
WO2018195376A1 (en) * 2017-04-21 2018-10-25 Ohio University Peptide-based inhibitors of mark family proteins
CN108802227A (zh) * 2018-06-19 2018-11-13 大连工业大学 生物活性多肽序列的联合鉴定方法
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
US20220031653A1 (en) * 2020-07-30 2022-02-03 United States Government As Represented By The Department Of Veterans Affairs Compounds for Treating Tauopathies and Restless Leg Syndrome and Methods of Using and Screening for Same
WO2022103897A1 (en) * 2020-11-11 2022-05-19 Health Research, Inc. Methods for disrupting mitochondrial unfolded protein response
WO2023107714A2 (en) * 2021-12-10 2023-06-15 Prothena Biosciences Limited Methods for treating neurological disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20090117543A1 (en) 2004-05-04 2009-05-07 President And Fellows Of Harvard College Methods and compositions for inducing sirtuins
US20060223812A1 (en) * 2004-07-17 2006-10-05 Max-Planck-Gesellschaft Zur Forderungder Wissenschaften, E.V. Treating neurodegenerative conditions
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CA2617532A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
CN102791725A (zh) * 2009-11-06 2012-11-21 J.大卫格莱斯顿学会 调节tau水平的方法和组合物

Also Published As

Publication number Publication date
EP2496594A1 (en) 2012-09-12
AU2010315780A1 (en) 2012-05-17
US9040521B2 (en) 2015-05-26
EP2496594B1 (en) 2018-01-17
DK2496594T3 (en) 2018-03-05
EA201290194A1 (ru) 2013-04-30
CA2778234A1 (en) 2011-05-12
CA2990678A1 (en) 2011-05-12
US20120225864A1 (en) 2012-09-06
ZA201202923B (en) 2013-06-26
JP5851409B2 (ja) 2016-02-03
US20160015733A1 (en) 2016-01-21
KR20120101053A (ko) 2012-09-12
CA2990678C (en) 2021-08-31
CN102791725A (zh) 2012-11-21
IL219445A0 (en) 2012-06-28
CA2778234C (en) 2018-05-15
EP2496594A4 (en) 2013-07-10
US9585907B2 (en) 2017-03-07
JP2013510086A (ja) 2013-03-21
WO2011056300A1 (en) 2011-05-12
BR112012010587A2 (pt) 2015-09-29
MX2012005300A (es) 2012-07-30

Similar Documents

Publication Publication Date Title
CL2012001103A1 (es) Método para reducir el nivel del polipéptido tau desacetilado en una célula, que comprende poner en contacto la célula con un agente que incrementa la actividad de un polipéptido que desacetila tau y/o un agente que disminuye la actividad de un polipéptido que acetila tau; y usos terapéuticos para tratar una tauopatía.
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
CL2012003625A1 (es) Una composicion acuosa que contiene bromhexina, en donde la composicion tiene una cantidad de azucar-alcoholes inferior a 10 g referida a 100 ml de la composicion; y su uso para la terapia secretorica en enfermedades broncopulmonares agudas y cronicas.
CL2007000876A1 (es) Uso de un antagonista del factor de crecimiento endotelial vascular (vegf) en combinacion con un segundo agente que comprende un agente reductor de celula mieloide para tratar un tumor resistente en un sujeto; y metodo de diagnostico del tumor.
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
CL2013000238A1 (es) Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos.
GT201400077A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
AR061772A1 (es) Composicion de alto contenido de ion fluoruro para el cuidado oral y metodo para mantener la actividad anticaries
BRPI0815824A2 (pt) Agente de reticulação, polímero de reticulação e seus usos
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112014024220A2 (pt) genes que codificam celulase
GT200900233A (es) Tratamientos de bananos
CL2015002955A1 (es) Proceso para tratar una corriente de colas que comprende agua y sólidos, el proceso comprende: (a) poner en contacto un agente gelificante y un activador con la corriente de colas, (b) atrapar los sólidos dentro de un gel producido a partir del agente gelificante, y (c) depositar el gel en un líquido.
IN2014DN08385A (es)
CO6700840A2 (es) Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia
DK2124640T3 (da) Glucoseisomerase til anvendelse i behandlingen af fruktoseintolerans
CL2012003689A1 (es) Metodo para blanquear pulpa que comprende contactar la pulpa en una solucion acuosa desde ph 2-7 con peroxidasa clasificada, una fuente de peroxido de hidrogeno y un mediador; composicion de blanqueado; y uso de dicha composicion.
BRPI0911573A2 (pt) preservativo com agente ativo localizado.
AR112044A1 (es) Solución de limpieza de membrana y método de limpieza de membrana acelerado mediante el uso de la misma
ECSP12012132A (es) Combinación de teobromina con un descongestivo y su uso para el tratamiento de la tos